110 related articles for article (PubMed ID: 26549588)
1. Sorafenib and novel multikinase inhibitors in AML.
Daver N; Konopleva M
Lancet Oncol; 2015 Dec; 16(16):1582-3. PubMed ID: 26549588
[No Abstract] [Full Text] [Related]
2. Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial.
Röllig C; Serve H; Hüttmann A; Noppeney R; Müller-Tidow C; Krug U; Baldus CD; Brandts CH; Kunzmann V; Einsele H; Krämer A; Schäfer-Eckart K; Neubauer A; Burchert A; Giagounidis A; Krause SW; Mackensen A; Aulitzky W; Herbst R; Hänel M; Kiani A; Frickhofen N; Kullmer J; Kaiser U; Link H; Geer T; Reichle A; Junghanß C; Repp R; Heits F; Dürk H; Hase J; Klut IM; Illmer T; Bornhäuser M; Schaich M; Parmentier S; Görner M; Thiede C; von Bonin M; Schetelig J; Kramer M; Berdel WE; Ehninger G;
Lancet Oncol; 2015 Dec; 16(16):1691-9. PubMed ID: 26549589
[TBL] [Abstract][Full Text] [Related]
3. High rate of hematological responses to sorafenib in FLT3-ITD acute myeloid leukemia relapsed after allogeneic hematopoietic stem cell transplantation.
De Freitas T; Marktel S; Piemontese S; Carrabba MG; Tresoldi C; Messina C; Lupo Stanghellini MT; Assanelli A; Corti C; Bernardi M; Peccatori J; Vago L; Ciceri F
Eur J Haematol; 2016 Jun; 96(6):629-36. PubMed ID: 26260140
[TBL] [Abstract][Full Text] [Related]
4. The role of sorafenib in hepatocellular carcinoma.
Gholam P
Clin Adv Hematol Oncol; 2015 Apr; 13(4):232-4. PubMed ID: 26352581
[No Abstract] [Full Text] [Related]
5. Azacitidine as post-remission consolidation for sorafenib-induced remission of Fms-like tyrosine kinase-3 internal tandem duplication positive acute myeloid leukemia.
Gill H; Man CH; Ip AH; Choi WW; Chow HC; Kwong YL; Leung AY
Haematologica; 2015 Jul; 100(7):e250-3. PubMed ID: 25820334
[No Abstract] [Full Text] [Related]
6. Sorafenib in combination with intensive chemotherapy in elderly patients with acute myeloid leukemia: results from a randomized, placebo-controlled trial.
Serve H; Krug U; Wagner R; Sauerland MC; Heinecke A; Brunnberg U; Schaich M; Ottmann O; Duyster J; Wandt H; Fischer T; Giagounidis A; Neubauer A; Reichle A; Aulitzky W; Noppeney R; Blau I; Kunzmann V; Stuhlmann R; Krämer A; Kreuzer KA; Brandts C; Steffen B; Thiede C; Müller-Tidow C; Ehninger G; Berdel WE
J Clin Oncol; 2013 Sep; 31(25):3110-8. PubMed ID: 23897964
[TBL] [Abstract][Full Text] [Related]
7. Maturing of renal cancer therapeutics.
Stadler WM
J Clin Oncol; 2014 Mar; 32(8):722-4. PubMed ID: 24516015
[No Abstract] [Full Text] [Related]
8. Outcome of FLT3-ITD-positive acute myeloid leukemia: impact of allogeneic stem cell transplantation and tyrosine kinase inhibitor treatment.
Fleischmann M; Schnetzke U; Schrenk KG; Schmidt V; Sayer HG; Hilgendorf I; Hochhaus A; Scholl S
J Cancer Res Clin Oncol; 2017 Feb; 143(2):337-345. PubMed ID: 27778197
[TBL] [Abstract][Full Text] [Related]
9. NRAS mutations in cutaneous T cell lymphoma (CTCL) sensitize tumors towards treatment with the multikinase inhibitor Sorafenib.
Kießling MK; Nicolay JP; Schlör T; Klemke CD; Süss D; Krammer PH; Gülow K
Oncotarget; 2017 Jul; 8(28):45687-45697. PubMed ID: 28537899
[TBL] [Abstract][Full Text] [Related]
10. [Sorafenib monotherapy for FLT3-ITD positive acute myeloid leukemia: a case report].
Jiang ZH; Feng FE; Lin XQ; Lu J
Zhonghua Xue Ye Xue Za Zhi; 2013 Aug; 34(8):736. PubMed ID: 23978034
[No Abstract] [Full Text] [Related]
11. Sorafenib: the gold standard therapy in advanced hepatocellular carcinoma and beyond.
Gadaleta-Caldarola G; Divella R; Mazzocca A; Infusino S; Ferraro E; Filippelli G; Daniele A; Sabbà C; Abbate I; Brandi M
Future Oncol; 2015; 11(16):2263-6. PubMed ID: 26260805
[No Abstract] [Full Text] [Related]
12. Complete remission of advanced hepatocellular carcinoma by radiofrequency ablation after sorafenib therapy.
Park JG; Park SY; Lee HW
World J Gastroenterol; 2015 Feb; 21(8):2568-72. PubMed ID: 25741170
[TBL] [Abstract][Full Text] [Related]
13. Brivanib and FOLFOX in hepatocellular carcinoma: finding the common themes among negative trials.
Kelley RK
J Clin Oncol; 2013 Oct; 31(28):3483-6. PubMed ID: 23980088
[No Abstract] [Full Text] [Related]
14. Inhibition of c-Kit by tyrosine kinase inhibitors.
Galanis A; Levis M
Haematologica; 2015 Mar; 100(3):e77-9. PubMed ID: 25425690
[No Abstract] [Full Text] [Related]
15. Successful molecular targeted treatment of AML in pregnancy with Azacitidine and Sorafenib with no adverse fetal outcomes.
Mahdi AJ; Gosrani D; Chakraborty M; Rees A; Conner C; Wilson K; Rayment R; Alvares C
Br J Haematol; 2018 Feb; 180(4):603-604. PubMed ID: 27766617
[No Abstract] [Full Text] [Related]
16. [Clinical Efficacy of Sorafenib Combined with Low Dose Cytarabine for Treating Patients with FLT3+ Relapsed and Refractory Acute Myeloid Leukemia].
Liu XS; Long H; Huang YX; Xu JH; Zhu JY; DU QF; Wu BY
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2016 Apr; 24(2):394-8. PubMed ID: 27150998
[TBL] [Abstract][Full Text] [Related]
17. Treatment of Post-transplant Relapse of FLT3-ITD Mutated AML Using 5-Azacytidine and Sorafenib Bitherapy.
Sid S; Rey J; Charbonnier A; D'Incan E; Mohty B; Blaise D; Vey N
Clin Lymphoma Myeloma Leuk; 2017 Apr; 17(4):241-242. PubMed ID: 28196687
[No Abstract] [Full Text] [Related]
18. Long-term survival of sorafenib-treated FLT3-ITD-positive acute myeloid leukaemia patients relapsing after allogeneic stem cell transplantation.
Metzelder SK; Schroeder T; Lübbert M; Ditschkowski M; Götze K; Scholl S; Meyer RG; Dreger P; Basara N; Fey MF; Salih HR; Finck A; Pabst T; Giagounidis A; Kobbe G; Wollmer E; Finke J; Neubauer A; Burchert A
Eur J Cancer; 2017 Nov; 86():233-239. PubMed ID: 29055209
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and feasibility of sorafenib as a maintenance agent after allogeneic hematopoietic stem cell transplantation for Fms-like tyrosine kinase 3-mutated acute myeloid leukemia.
Battipaglia G; Ruggeri A; Massoud R; El Cheikh J; Jestin M; Antar A; Ahmed SO; Rasheed W; Shaheen M; Belhocine R; Brissot E; Dulery R; Eder S; Giannotti F; Isnard F; Lapusan S; Rubio MT; Vekhoff A; Aljurf M; Legrand O; Mohty M; Bazarbachi A
Cancer; 2017 Aug; 123(15):2867-2874. PubMed ID: 28387928
[TBL] [Abstract][Full Text] [Related]
20. Final report of phase II study of sorafenib, cytarabine and idarubicin for initial therapy in younger patients with acute myeloid leukemia.
Ravandi F; Arana Yi C; Cortes JE; Levis M; Faderl S; Garcia-Manero G; Jabbour E; Konopleva M; O'Brien S; Estrov Z; Borthakur G; Thomas D; Pierce S; Brandt M; Pratz K; Luthra R; Andreeff M; Kantarjian H
Leukemia; 2014 Jul; 28(7):1543-5. PubMed ID: 24487412
[No Abstract] [Full Text] [Related]
[Next] [New Search]
